Addex Therapeutics Ltd. (ADXN) Cash & Equivalents (2022 - 2024)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Addex Therapeutics' Cash & Equivalents history spans 3 years, with the latest figure at $3.8 million for Q4 2024.

• For Q4 2024, Cash & Equivalents fell 12.46% year-over-year to $3.8 million; the TTM value through Dec 2024 reached $3.8 million, down 12.46%, while the annual FY2024 figure was $3.8 million, 11.74% down from the prior year.
• Cash & Equivalents for Q4 2024 was $3.8 million at Addex Therapeutics, down from $4.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $7.2 million in Q4 2022 and bottomed at $3.8 million in Q4 2024.
• The 3-year median for Cash & Equivalents is $4.4 million (2023), against an average of $5.1 million.
• The largest annual shift saw Cash & Equivalents tumbled 39.66% in 2023 before it fell 12.46% in 2024.
• A 3-year view of Cash & Equivalents shows it stood at $7.2 million in 2022, then crashed by 39.66% to $4.4 million in 2023, then decreased by 12.46% to $3.8 million in 2024.
• Per Business Quant, the three most recent readings for ADXN's Cash & Equivalents are $3.8 million (Q4 2024), $4.4 million (Q4 2023), and $7.2 million (Q4 2022).

Peer Comparison